Our Impact
We address some of the most significant challenges faced by modern medicine.
Our Approach
We are an Asian biologics company developing treatments for patients worldwide.
Our Focus
We optimize a series of innovative drug candidates for oncology and inflammatory disorders.
Our People
Our global team ensures a truly holistic approach to drug development.
Our Aim
To provide patients with breakthrough, life-saving treatments.
Previous
Next

Company

Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. We are developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide.

Mission

We develop revolutionary remedies for a healthy, happy world.

Vision

We strive to enable access to treatment options for patients for whom no effective standard of care exists. We aim to be one of the first Asian biologics companies to advance a novel biologic product from pre-clinical studies to BLA submission and commercial launch, and we are developing a portfolio of novel solutions to treat serious diseases for patients worldwide.

Values

Revolutionary

Exploring new frontiers of innovation and treatments

Brave

Striving to improve and drive bold initiatives to deliver best outcomes for patients

Collaborative

Working together to address needs of patients, physicians and customers

Passionate

Improving the standard of care for patients through our pursuit of innovative biological therapies

Trustworthy

Building trust with employees and partners through transparency, consistency, and reliability

What’s Going On

Our innovative assets have recently achieved significant milestones, including the completion of global Phase III clinical trials and the receipt of orphan drug designation. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.

Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment

Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia

Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease

Evive Announces Initiation of a Phase I Trial of A-319 to Treat Patients with B Cell Malignancies

Evive Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies

Evive’s F-652 Shows Positive Results in “An Open Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy in Patients with Alcoholic Hepatitis”